1. 792OA randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC). (23rd October 2018) Authors: Chi, K N; Taavitsainen, S; Iqbal, N; Ferrario, C; Ong, M; Wadhwa, D; Hotte, S J; Lo, G; Tran, B; Azad, A; Wood, L; Gingerich, J R; North, S; Pezaro, C V; Ruether, D; Sridhar, S S; Annala, M; Bacon, J; Wyatt, A W Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗